



SEKISUI MEDICAL CO., LTD.  
Confidence Inspired by Quality

June 1, 2026

Alchemedicine, Inc.  
Sekisui Medical Co., Ltd.

## Announcement of Collaborative Framework for Non-Clinical Research and Capital Alliance between Alchemedicine and Sekisui Medical

Alchemedicine, Inc. (Head Office: Tsukuba, Ibaraki; President & CEO: Keigo Tanaka; hereafter “Alchemedicine”) and Sekisui Medical Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Hiroyuki Yamashita; hereafter “Sekisui Medical”) announce that they have established a collaborative framework to accelerate the non-clinical research of new drug candidates discovered by Alchemedicine. In conjunction with this initiative, Alchemedicine has implemented a third-party allotment of shares to Sekisui Medical, and Sekisui Medical has subscribed to the allotment.

Under this collaborative framework, Alchemedicine will outsource to Sekisui Medical a part of preclinical research activities related to CMC (Chemistry, Manufacturing and Control), efficacy, safety, and pharmacokinetic studies for its novel drug candidates discovered by Alchemedicine. Sekisui Medical will support Alchemedicine’s research and development by leveraging its extensive experience in CMC research, the manufacture of APIs (active pharmaceutical ingredients) and intermediates as well as discovery and preclinical studies.

Through this partnership, both companies will work together to discover life-changing treatments for various diseases successively and contribute to the realization of a healthy and sustainable world.

### **About Alchemedicine, Inc.**

Alchemedicine is focused on the discovery of small-molecule drugs using the proprietary HiSAP™ medicinal chemistry platform under a vision of “We successively discover life changing treatments for various diseases that make a lasting positive contribution to society.”

Alchemedicine uses HiSAP™ to quickly create drug candidate compounds with improved efficacy and safety. As HiSAP™ has a broad range of applicability, Alchemedicine simultaneously performs R&D in various different therapeutic areas. For more information, please visit <https://alchemedicine.com/en/>

## **About Sekisui Medical Co., Ltd.**

Sekisui Medical aims to contribute to the realization of a healthy and sustainable world by providing intelligent solutions with science that improve the health of people around the world. In addition to consolidating and expanding our key diagnostics and pharmaceutical sciences businesses in Japan, we are accelerating our global business expansion in regions such as North America, Europe and Asia. Our pharmaceutical sciences business consisting of two business portfolios - the Pharma & Enzymes Business Department and the Drug Development Solutions Business Department - underpins the foundations of the medical field. For more information, please visit <https://www.sekisuimedical.jp/english/>

<sup>1</sup> HiSAP™ is a medicinal chemistry platform comprised of over 35,000 novel core structures (HiSAP Core Structures) and an in-silico compound-design support system (HiSAPort System). HiSAP™ enables rapid improvement of efficacy and/or safety issues of existing bioactive compounds across a broad range of therapeutic areas, sustaining desirable drug profiles.

Contact information:

### **Alchemedicine**

Administration Department

E-mail: [info@alchemedicine.com](mailto:info@alchemedicine.com)

### **Sekisui Medical**

Please contact us through the inquiry form below.

<https://www.sekisuimedical.jp/english/inquiry/>